Greenwood Capital Associates’s CRISPR Therapeutics CRSP Stock Holding History

Greenwood Capital Associates’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$334K	Buy	+6,121	New	+$323K	0.03%	258
2025 Q1	–	Sell	-6,733	Closed	-$265K	–	242
2024 Q4	$265K	Sell	6,733 -233	-3%	-$11K	0.03%	226
2024 Q3	$327K	Sell	6,966 -162	-2%	-$8.22K	0.04%	208
2024 Q2	$385K	Buy	7,128 +434	+6%	+$25.1K	0.05%	202
2024 Q1	$456K	Sell	6,694 -107	-2%	-$7.66K	0.06%	206
2023 Q4	$426K	Buy	6,801 +1,306	+24%	+$72.2K	0.06%	203
2023 Q3	$249K	Buy	5,495 +31	+0.6%	+$1.6K	0.04%	234
2023 Q2	$307K	Sell	5,464 -167	-3%	-$9.48K	0.04%	217
2023 Q1	$255K	Sell	5,631 -59,374	-91%	-$2.88M	0.04%	218
2022 Q4	$2.64M	Buy	65,005 +4,950	+8%	+$263K	0.43%	61
2022 Q3	$3.92M	Buy	+60,055	New	+$4.35M	0.67%	49

Other funds holding CRSP

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

OAG

Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

GSK plc London $602M AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

SOCM

SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Greenwood Capital Associates's CRSP Position: Q2 2026 in Review

Greenwood Capital Associates opened a new position in CRISPR Therapeutics (CRSP) in Q2 2026: 6,121 shares worth $334K. The stake represents 0.03% of the portfolio and ranks #258 among its holdings. This is a return to the name: Greenwood Capital Associates previously reported a position in CRSP as recently as Q4 2024.

Greenwood Capital Associates first reported a position in CRSP in Q3 2022 and has held it in 11 quarters since. The position peaked at $3.92M in Q3 2022. 524 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

Greenwood Capital Associates held 6,121 shares of CRISPR Therapeutics worth $334K as of Q2 2026.
CRISPR Therapeutics was a new Greenwood Capital Associates position in Q2 2026.
CRISPR Therapeutics made up 0.03% of Greenwood Capital Associates's portfolio in Q2 2026, its #258 holding.
Greenwood Capital Associates first reported a position in CRISPR Therapeutics in Q3 2022 and has held it in 11 quarters since.
Greenwood Capital Associates's CRISPR Therapeutics position peaked at $3.92M in Q3 2022.
524 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on Greenwood Capital Associates's 13F filing for Q2 2026, filed 28 Jul 2026.